+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Insomnia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749232
  • Report
  • 90 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • Evotec AG
  • Heptares Therapeutics Ltd
  • Janssen Pharmaceuticals
  • Leading BioSciences Inc
  • Merck & Co Inc
  • MORE
The global demand for Insomnia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Insomnia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Insomnia pipeline companies from advancing their products into Phase 3 or Phase 4.

Insomnia Report Description

The 2019 pipeline study on Insomnia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Insomnia pipeline compounds.

The Insomnia pipeline guide presents information on all active drugs currently being developed for Insomnia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Insomnia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Insomnia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Insomnia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Insomnia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Insomnia pipeline report includes
  • An overview of Insomnia disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Insomnia pipeline
  • Company wise list of Insomnia pipeline
  • Mechanism of Action wise Insomnia pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Insomnia pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Insomnia pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Insomnia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • Evotec AG
  • Heptares Therapeutics Ltd
  • Janssen Pharmaceuticals
  • Leading BioSciences Inc
  • Merck & Co Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Insomnia Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Insomnia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Insomnia pipeline, H1- 2019
3.5 Mechanism of Action wise Insomnia Pipeline Candidates

4 Alexza Pharmaceuticals Inc Insomnia Pipeline Details
4.1 Alexza Pharmaceuticals Inc Business Profile
4.2 Alexza Pharmaceuticals Inc Insomnia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Amherst Pharmaceuticals LLC Insomnia Pipeline Details
5.1 Amherst Pharmaceuticals LLC Business Profile
5.2 Amherst Pharmaceuticals LLC Insomnia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Blake Insomnia Therapeutics Inc Insomnia Pipeline Details
6.1 Blake Insomnia Therapeutics Inc Business Profile
6.2 Blake Insomnia Therapeutics Inc Insomnia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Cennerv Pharmaceuticals Ltd Insomnia Pipeline Details
7.1 Cennerv Pharmaceuticals Ltd Business Profile
7.2 Cennerv Pharmaceuticals Ltd Insomnia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Cosmas Therapeutics Development Inc Insomnia Pipeline Details
8.1 Cosmas Therapeutics Development Inc Business Profile
8.2 Cosmas Therapeutics Development Inc Insomnia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Druggability Technologies Holdings Ltd Insomnia Pipeline Details
9.1 Druggability Technologies Holdings Ltd Business Profile
9.2 Druggability Technologies Holdings Ltd Insomnia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Eisai Co Ltd Insomnia Pipeline Details
10.1 Eisai Co Ltd Business Profile
10.2 Eisai Co Ltd Insomnia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Evotec AG Insomnia Pipeline Details
11.1 Evotec AG Business Profile
11.2 Evotec AG Insomnia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Grupo Ferrer Internacional SA Insomnia Pipeline Details
12.1 Grupo Ferrer Internacional SA Business Profile
12.2 Grupo Ferrer Internacional SA Insomnia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Heptares Therapeutics Ltd Insomnia Pipeline Details
13.1 Heptares Therapeutics Ltd Business Profile
13.2 Heptares Therapeutics Ltd Insomnia Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Idorsia Pharmaceutical Ltd Insomnia Pipeline Details
14.1 Idorsia Pharmaceutical Ltd Business Profile
14.2 Idorsia Pharmaceutical Ltd Insomnia Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 Intra-Cellular Therapies Inc Insomnia Pipeline Details
15.1 Intra-Cellular Therapies Inc Business Profile
15.2 Intra-Cellular Therapies Inc Insomnia Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 Janssen Pharmaceuticals Insomnia Pipeline Details
16.1 Janssen Pharmaceuticals Business Profile
16.2 Janssen Pharmaceuticals Insomnia Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 Leading BioSciences Inc Insomnia Pipeline Details
17.1 Leading BioSciences Inc Business Profile
17.2 Leading BioSciences Inc Insomnia Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 Linnet BioPharmaceuticals Inc Insomnia Pipeline Details
18.1 Linnet BioPharmaceuticals Inc Business Profile
18.2 Linnet BioPharmaceuticals Inc Insomnia Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 Merck & Co Inc Insomnia Pipeline Details
19.1 Merck & Co Inc Business Profile
19.2 Merck & Co Inc Insomnia Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 NB Health Laboratory Co Ltd Insomnia Pipeline Details
20.1 NB Health Laboratory Co Ltd Business Profile
20.2 NB Health Laboratory Co Ltd Insomnia Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 Neurim Pharmaceuticals Ltd Insomnia Pipeline Details
21.1 Neurim Pharmaceuticals Ltd Business Profile
21.2 Neurim Pharmaceuticals Ltd Insomnia Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 NeuroFix Therapeutics LLC Insomnia Pipeline Details
22.1 NeuroFix Therapeutics LLC Business Profile
22.2 NeuroFix Therapeutics LLC Insomnia Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 Overseas Pharmaceuticals Ltd Insomnia Pipeline Details
23.1 Overseas Pharmaceuticals Ltd Business Profile
23.2 Overseas Pharmaceuticals Ltd Insomnia Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24 Purdue Pharma LP Insomnia Pipeline Details
24.1 Purdue Pharma LP Business Profile
24.2 Purdue Pharma LP Insomnia Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25 Reviva Pharmaceuticals Inc Insomnia Pipeline Details
25.1 Reviva Pharmaceuticals Inc Business Profile
25.2 Reviva Pharmaceuticals Inc Insomnia Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26 Sage Therapeutics Inc Insomnia Pipeline Details
26.1 Sage Therapeutics Inc Business Profile
26.2 Sage Therapeutics Inc Insomnia Drug Details
26.3 Drug Snapshot
26.3.1 Originator
26.3.2 Collaborator/Co-Developer
26.3.3 Route of Administration
26.3.4 Orphan Drug/Fast Track/Special Designation
26.3.5 Geography
26.3.6 Type of Molecular Entity
26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27 Shionogi & Co Ltd Insomnia Pipeline Details
27.1 Shionogi & Co Ltd Business Profile
27.2 Shionogi & Co Ltd Insomnia Drug Details
27.3 Drug Snapshot
27.3.1 Originator
27.3.2 Collaborator/Co-Developer
27.3.3 Route of Administration
27.3.4 Orphan Drug/Fast Track/Special Designation
27.3.5 Geography
27.3.6 Type of Molecular Entity
27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28 Taisho Pharmaceutical Holdings Co Ltd Insomnia Pipeline Details
28.1 Taisho Pharmaceutical Holdings Co Ltd Business Profile
28.2 Taisho Pharmaceutical Holdings Co Ltd Insomnia Drug Details
28.3 Drug Snapshot
28.3.1 Originator
28.3.2 Collaborator/Co-Developer
28.3.3 Route of Administration
28.3.4 Orphan Drug/Fast Track/Special Designation
28.3.5 Geography
28.3.6 Type of Molecular Entity
28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29 Zelda Therapeutics Pty Ltd Insomnia Pipeline Details
29.1 Zelda Therapeutics Pty Ltd Business Profile
29.2 Zelda Therapeutics Pty Ltd Insomnia Drug Details
29.3 Drug Snapshot
29.3.1 Originator
29.3.2 Collaborator/Co-Developer
29.3.3 Route of Administration
29.3.4 Orphan Drug/Fast Track/Special Designation
29.3.5 Geography
29.3.6 Type of Molecular Entity
29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

30. Latest Insomnia Drug Pipeline Developments, 2019

31. Appendix
31.1 About Us
31.2 Sources and Methodology
31.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexza Pharmaceuticals Inc
  • Amherst Pharmaceuticals LLC
  • Blake Insomnia Therapeutics Inc
  • Cennerv Pharmaceuticals Ltd
  • Cosmas Therapeutics Development Inc
  • Druggability Technologies Holdings Ltd
  • Eisai Co Ltd
  • Evotec AG
  • Grupo Ferrer Internacional SA
  • Heptares Therapeutics Ltd
  • Idorsia Pharmaceutical Ltd
  • Intra-Cellular Therapies Inc
  • Janssen Pharmaceuticals
  • Leading BioSciences Inc
  • Linnet BioPharmaceuticals Inc
  • Merck & Co Inc
  • NB Health Laboratory Co Ltd
  • Neurim Pharmaceuticals Ltd
  • NeuroFix Therapeutics LLC
  • Overseas Pharmaceuticals Ltd
  • Purdue Pharma LP
  • Reviva Pharmaceuticals Inc
  • Sage Therapeutics Inc
  • Shionogi & Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Zelda Therapeutics Pty Ltd
Note: Product cover images may vary from those shown
Adroll
adroll